Encompass Health Corp EHC
We are the nation's largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment, using advanced technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence and quality of life. We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas. As of December 31, 2025, we operated 173 inpatient rehabilitation hospitals. We are committed to delivering high-quality, cost-effective patient care. For 2025, we were named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and ranked among Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $4.01B | $3.57B | $4.61B | $4.28B | $3.91B | $3.64B |
| SG&A | $236.2M | $209.2M | $201.7M | $154.3M | $169.5M | $151.6M | $247.0M | $220.2M | $171.7M | $133.4M |
| Total operating expenses | $4.88B | $4.51B | $4.07B | $3.72B | $3.36B | $3.04B | $3.91B | $3.65B | $3.26B | $2.99B |
| Operating income | — | — | — | $539.5M | $559.6M | $563.9M | $612.1M | $555.2M | $578.3M | $588.1M |
| Interest expense | $123.2M | $137.4M | $143.5M | $175.7M | $164.3M | $183.7M | $159.7M | $147.3M | $154.4M | $172.1M |
| Pre-tax income | $953.0M | $749.6M | $607.2M | $450.8M | $505.0M | $352.9M | $562.3M | $493.2M | $496.4M | $482.0M |
| Income tax | $192.9M | $150.2M | $132.2M | $100.1M | $101.9M | $74.7M | $115.9M | $118.9M | $145.8M | $163.9M |
| Net income | $759.1M | $596.6M | $463.0M | $365.9M | $517.2M | $284.2M | $358.7M | $292.3M | $271.1M | $247.6M |
| EPS, basic | 5.62 | 4.53 | 3.51 | 2.72 | 4.15 | 2.87 | 3.65 | 2.98 | 2.88 | 2.77 |
| EPS, diluted | 5.54 | 4.46 | 3.47 | 2.70 | 4.11 | 2.85 | 3.61 | 2.93 | 2.84 | 2.59 |
| Shares, diluted (wtd. avg.) | $102.2M | $102.2M | $101.3M | $100.4M | $100.2M | $99.8M | $99.4M | $99.8M | $99.3M | $99.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $72.2M | $85.4M | $69.1M | $21.8M | $49.4M | $185.6M | $60.0M | $69.2M | $54.4M | $40.5M |
| Receivables | $613.4M | $593.0M | $599.8M | $524.8M | $502.1M | $563.0M | $498.7M | $459.9M | $459.5M | $432.0M |
| Total current assets | $905.9M | $886.9M | $841.8M | $717.2M | $921.4M | $948.6M | $755.8M | $662.1M | $702.2M | $654.5M |
| Property, plant and equipment | — | — | — | — | — | — | $1.96B | $1.63B | $1.52B | $1.39B |
| Goodwill | $1.32B | $1.28B | $1.28B | $1.26B | $1.24B | $1.23B | $1.22B | $2.10B | $1.97B | $1.93B |
| Other intangibles | $308.3M | $297.8M | $278.2M | $282.3M | $158.4M | $431.3M | $476.3M | $443.4M | $403.1M | $411.3M |
| Total assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B | $6.45B | $6.08B | $5.17B | $4.86B | $4.68B |
| Accounts payable | $178.2M | $171.0M | $170.0M | $132.9M | $134.0M | $115.0M | $94.6M | $90.0M | $78.4M | $68.3M |
| Total current liabilities | $836.4M | $841.0M | $656.4M | $575.9M | $748.8M | $717.3M | $721.0M | $672.5M | $517.5M | $475.6M |
| Total liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B | $4.44B | $4.15B | $3.36B | $3.25B | $3.61B |
| Retained earnings | $1.29B | $796.7M | $406.5M | $115.7M | $141.8M | -$242.3M | -$526.5M | -$885.2M | -$1.18B | -$1.45B |
| Total equity | $2.44B | $2.07B | $2.26B | $1.83B | $2.36B | $1.97B | $1.69B | $1.56B | $1.40B | $910.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.18B | $1.00B | $850.8M | $705.8M | $715.8M | $704.7M | $635.3M | $762.4M | $658.3M | $640.2M |
| Depreciation and amortisation | $327.9M | $299.6M | $273.9M | $243.6M | $219.6M | $203.0M | $218.7M | $199.7M | $183.8M | $172.6M |
| Stock-based compensation | $56.5M | $48.3M | $50.6M | $29.2M | $29.1M | $25.6M | $114.4M | $85.9M | $47.7M | $27.4M |
| Capital expenditure | $736.4M | $642.5M | $583.1M | $584.1M | $545.7M | $392.8M | $372.4M | $254.5M | $225.8M | $177.7M |
| Investing cash flow | -$764.6M | -$653.3M | -$602.8M | -$627.0M | -$666.3M | -$407.5M | -$657.4M | -$424.5M | -$283.0M | -$229.9M |
| Financing cash flow | -$431.2M | -$330.6M | -$197.2M | -$145.7M | -$240.1M | -$145.9M | $48.2M | -$321.2M | -$359.9M | -$416.4M |
| Dividends paid | $71.1M | $62.8M | $60.4M | $99.0M | $112.2M | $111.8M | $108.7M | $100.8M | $91.5M | $83.8M |
| Buybacks | $158.0M | $31.1M | $0 | $0 | $0 | $6.1M | $45.9M | $0 | $38.1M | $65.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000785161-26-000105.
Others in SIC 8060
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MD | Pediatrix Medical Group, Inc. | $2.20B | 13.9x | -4.9% |